PRAX Quote, Financials, Valuation and Earnings

DocGo has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -2.7%. Praxis Precision Medicines's return on equity of -59.11% beat DocGo's return on equity of 6.33%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 154.67%. On the other hand DocGo has an analysts' consensus of $5.05 which suggests that it could grow by 260.62%. Given that DocGo has higher upside potential than Praxis Precision Medicines, analysts believe DocGo is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DocGo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DocGo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. DocGo pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than DocGo quarterly revenues of $120.8M. Praxis Precision Medicines's net income of -$69.3M is lower than DocGo's net income of -$3.3M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while DocGo's PE ratio is 8.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 88.29x versus 0.25x for DocGo. Usually stocks with elevated PS ratios are considered overvalued.

IGM Biosciences has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -8894.9%. Praxis Precision Medicines's return on equity of -59.11% beat IGM Biosciences's return on equity of -159.45%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 154.67%. On the other hand IGM Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 65.93%. Given that Praxis Precision Medicines has higher upside potential than IGM Biosciences, analysts believe Praxis Precision Medicines is more attractive than IGM Biosciences.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGM Biosciences has a beta of 0.610, suggesting its less volatile than the S&P 500 by 38.975%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGM Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. IGM Biosciences pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than IGM Biosciences quarterly revenues of $412K. Praxis Precision Medicines's net income of -$69.3M is lower than IGM Biosciences's net income of -$36.6M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while IGM Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 88.29x versus 25.52x for IGM Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -687.61%. Praxis Precision Medicines's return on equity of -59.11% beat Intellia Therapeutics's return on equity of -56.9%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 154.67%. On the other hand Intellia Therapeutics has an analysts' consensus of $40.56 which suggests that it could grow by 399.45%. Given that Intellia Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Intellia Therapeutics is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.332, suggesting its more volatile than the S&P 500 by 133.227%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Intellia Therapeutics quarterly revenues of $16.6M. Praxis Precision Medicines's net income of -$69.3M is higher than Intellia Therapeutics's net income of -$114.3M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 88.29x versus 17.97x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -296.76%. Praxis Precision Medicines's return on equity of -59.11% beat Zevra Therapeutics's return on equity of -208.85%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 154.67%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 174.78%. Given that Zevra Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Zevra Therapeutics is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.870, suggesting its more volatile than the S&P 500 by 87.041%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Zevra Therapeutics quarterly revenues of $12M. Praxis Precision Medicines's net income of -$69.3M is lower than Zevra Therapeutics's net income of -$35.7M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 88.29x versus 15.41x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.